PredIcting SterOid DepeNdEnt LivEr InjuRy with Polyreactive Immunoglobulin G

Launched by HANNOVER MEDICAL SCHOOL · Apr 11, 2023

Keywords

ClinConnect Summary

This clinical trial is studying a new way to help diagnose autoimmune hepatitis, a condition where the body's immune system attacks the liver. Researchers are looking at a specific type of antibody, called polyreactive immunoglobulin G (pIgG), to see if it can accurately identify autoimmune hepatitis compared to other liver diseases. This is important because sometimes autoimmune hepatitis can look very similar to liver injuries caused by medications or other factors, and getting the right diagnosis is crucial for treatment.

To participate in the trial, individuals must have a liver biopsy to investigate any liver disease and provide informed consent. They should not be on any immunosuppressive treatment at the time of the biopsy. Participants will give a blood sample and will be followed up after six months to check if they need long-term treatment with steroids, which are often used to manage autoimmune conditions. This study is currently recruiting participants of all ages and genders who meet the criteria.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Diagnostic liver biopsy for the work-up of any liver disease
• • Informed consent
• • Definition of any liver disease according to current societal guidelines
• Exclusion Criteria:
• • No ongoing immunosuppression at the liver biopsy or prior to the liver biopsy
• • Liver biopsies for the grading or staging of an already known liver disease (e.g. non-alcoholic fatty liver disease (NAFLD), Hepatitis B/D Virus Infections (HBV/HDV Infection), ...)